Imidazolecarboxamide FAAH Inhibitors with Peripheral Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current FAAH inhibitors, such as those disclosed in WO 2010/074588, are either weak or lack peripheral selectivity and metabolic stability, limiting their effectiveness in modulating the endocannabinoid system for treating various diseases associated with the FAAH enzyme.
Innovation Solution
Development of novel compounds with specific structures, such as N-Methyl-4-(3-(sulfamoylamino)phenyl)-N-(tetrahydro-2H-pyran-4-yl)-1H-imidazole-1-carboxamide, which exhibit potent FAAH inhibition, high peripheral selectivity, and metabolic stability, formulated into pharmaceutical compositions for administration via various routes to treat conditions linked to FAAH substrates.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional FAAH inhibitors are used, then FAAH inhibition is achieved, but peripheral selectivity and metabolic stability are insufficient
Solution Approach 1:
The patent applies local quality by designing the inhibitor molecule with specific functional groups positioned to interact differently with peripheral FAAH versus central FAAH. The compounds contain specific substituents at defined positions on the core structure that create localized interactions with peripheral tissue FAAH enzymes, achieving selective inhibition in peripheral tissues while minimizing central nervous system effects.
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters of the inhibitor molecules, including substituent types, positions, and stereochemistry. By optimizing these chemical parameters, the compounds achieve enhanced metabolic stability through resistance to enzymatic degradation while maintaining potent FAAH inhibition activity.
2Reliability
If conventional FAAH inhibitors are used, then FAAH inhibition is achieved, but metabolic stability is poor
Solution Approach 1:
The patent employs parameter changes by systematically varying chemical parameters of the inhibitor molecules, including substituent types, positions, and stereochemistry. By optimizing these chemical parameters, the compounds achieve enhanced metabolic stability through resistance to enzymatic degradation while maintaining potent FAAH inhibition activity.
Solution Approach 2:
The patent applies composite materials by combining multiple functional groups and structural elements into a single inhibitor molecule. The compounds integrate a core imidazole or triazole structure with specific aromatic substituents, amide groups, and heterocyclic moieties, creating a composite molecular structure that simultaneously achieves potent enzyme inhibition and resistance to metabolic breakdown.
3Adaptability or versatility
If imidazole structure is added to carbamate compounds, then structural diversity is increased, but FAAH inhibition potency decreases
Solution Approach 1:
The patent applies local quality by precisely positioning the imidazole or triazole ring at specific locations within the molecular structure and configuring its orientation to optimize interactions with the FAAH active site. This localized structural arrangement ensures that the heterocyclic group contributes to binding affinity rather than reducing it, resolving the contradiction between structural diversity and inhibition potency.
Solution Approach 2:
The patent employs asymmetry by using chiral imidazole or triazole rings with specific stereochemistry, creating non-superimposable mirror images that can selectively interact with the asymmetric binding site of FAAH. This asymmetric design allows the compounds to maintain high potency while achieving structural diversity through different enantiomeric forms.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds demonstrate enhanced FAAH inhibition in peripheral tissues with improved metabolic stability, offering better therapeutic outcomes for conditions like pain, neurological disorders, and inflammatory diseases compared to existing inhibitors.
Implementation Method 1
FAAH enzyme breaks down fatty acid amides such as anandamide... Anandamide is degraded by the fatty acid amide hydrolase (FAAH) enzyme... inhibitors of FAAH lead to elevated anandamide levels... compounds... have been found to modulate the activity of the enzyme fatty acid amide hydrolase (FAAH)... exhibit potent FAAH inhibition
Data Source
AI summary
A compound having a structure selected from the following: or a pharmaceutically acceptable salt thereof. The compound may be used as an inhibitor of fatty acid amide hydrolase.